PROTAC BRD9 Degrader-12
PROTAC BRD9 Degrader-12 is a BRD9 PROTAC degrader, with DC50 values of 57 pM and 62 pM against BRD9 and IKZF1, respectively. PROTAC BRD9 Degrader-12 promotes CRL-CRBN-dependent ubiquitination and proteasome-mediated BRD9 degradation by simultaneously binding to BRD9 and CRBN, and concurrently recruits IKZF1 as a neosubstrate via CRBN to induce its degradation. PROTAC BRD9 Degrader-12 selectively degrades BRD9 and IKZF1. The synergistic degradation of BRD9/IKZF1 downregulates MYC-related signaling, induces apoptosis and S-phase cell cycle arrest, and thereby inhibits the proliferation of hematological malignant cells. PROTAC BRD9 Degrader-12 is used for research related to hematological malignancies.
(Pink: BRD9 ligand (HY-175915); Blue: Cereblon E3 ligase ligand; Black: linker).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C47H45N5O6
- Masse moléculaire:775.89
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
[1]|
BRD9 57 pM (DC50) |
IKZF1 62 pM (DC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RPMI-8226 | IC50 |
0.8 nM
|
Inhibition of Cell Growth
Inhibition of Cell Growth
|
acs.jmedchem.6c00801 |
| HL-60 | IC50 |
65.3 nM
|
Inhibition of Cell Growth
Inhibition of Cell Growth
|
acs.jmedchem.6c00801 |
| RS4-11 | IC50 |
0.2 nM
|
Inhibition of Cell Growth
Inhibition of Cell Growth
|
acs.jmedchem.6c00801 |
| REH | IC50 |
962.7 nM
|
Inhibition of Cell Growth
Inhibition of Cell Growth
|
acs.jmedchem.6c00801 |
| OCI-Ly1 | IC50 |
0.9 nM
|
Inhibition of Cell Growth
Inhibition of Cell Growth
|
acs.jmedchem.6c00801 |
| OCI-Ly3 | IC50 |
0.1 nM
|
Inhibition of Cell Growth
Inhibition of Cell Growth
|
acs.jmedchem.6c00801 |
| OCI-Ly10 | IC50 |
0.5 nM
|
Inhibition of Cell Growth
Inhibition of Cell Growth
|
acs.jmedchem.6c00801 |
| SU-DHL-4 | IC50 |
229.5 nM
|
Inhibition of Cell Growth
Inhibition of Cell Growth
|
acs.jmedchem.6c00801 |
| Z-138 | IC50 |
587 nM
|
Inhibition of Cell Growth
Inhibition of Cell Growth
|
acs.jmedchem.6c00801 |
| C-33-A | IC50 |
1029.7 nM
|
Inhibition of Cell Growth
Inhibition of Cell Growth
|
acs.jmedchem.6c00801 |
| MIA PaCa-2 | IC50 |
1188 nM
|
Inhibition of Cell Growth
Inhibition of Cell Growth
|
acs.jmedchem.6c00801 |
In Vitro
PROTAC BRD9 Degrader-12 (compound B8) induces dose-dependent cooperative degradation of BRD9 and IKZF1 in MV4-11 cells, with DC50 values of 57 pM and 62 pM for BRD9 and IKZF1, respectively. At 1 nM, it induces approximately 90% BRD9 degradation and nearly complete clearance of IKZF1, while no obvious GSPT1 degradation is observed[1].
PROTAC BRD9 Degrader-12 (1 nM) initiates BRD9 degradation at approximately 4 h and achieves near-complete clearance at 12 h; IKZF1 degradation occurs more rapidly, with an approximately 50% reduction within 1 h and near-complete clearance at 4 h[1].
PROTAC BRD9 Degrader-12-mediated degradation of BRD9 and IKZF1 is significantly inhibited by the proteasome inhibitor MG-132 or the NEDD8-activating enzyme inhibitor MLN4924. Competitive treatment with the BRD9 ligand I-BRD9 or the CRBN ligand pomalidomide similarly attenuates BRD9 degradation, indicating that this process depends on the formation of the BRD9/PROTAC/CRBN ternary complex, CRL-CRBN-dependent ubiquitination, and the proteasomal pathway[1].
PROTAC BRD9 Degrader-12 does not induce significant degradation of BRD7 or BRD4 in MV4-11 cells. In quantitative proteomic analysis of OCI-ly1 cells, BRD9 and IKZF1 are identified as the major degraded proteins, while IKZF3 undergoes only moderate degradation. No obvious degradation of CK1α, GSPT1, IKZF2, and TP63 is detected, and multiple zinc finger proteins remain largely unaffected[1].
PROTAC BRD9 Degrader-12 exerts a dose-dependent synergistic degradation effect on BRD9 and IKZF1 in RPMI-8226 and OCI-ly1 cells, with a maximum degradation level of approximately 99% at 1 nM[1].
PROTAC BRD9 Degrader-12 (1-1000 nM; 24 h) dose-dependently increases the proportion of apoptotic cells detected by Annexin V/PI assay in MV4-11 cells, with the total apoptotic cell proportion rising to 24.9% at 1 μM[1].
PROTAC BRD9 Degrader-12 (1-1000 nM; 24 h) alters the cell cycle distribution of MV4-11 cells in a dose-dependent manner, causing cell accumulation in the S phase accompanied by changes in the proportion of the G1 phase[1].
PROTAC BRD9 Degrader-12 (7 days) exhibits broad antiproliferative activity against a variety of hematological malignancy cells, with IC50 values of 0.2, 0.9, 0.1, and 0.5 nM in RS4;11, OCI-ly1, OCI-ly3, and OCI-ly10 cells, respectively, and IC50 values all below 0.2 nM in SU-DHL-2, Granta-519, and Jeko-1 cells; its activity against the majority of tested solid tumor cells is generally weak[1].
PROTAC BRD9 Degrader-12 (1-10 nM) only slightly reduces MYC mRNA in OCI-ly10 cells at 24 h, but significantly inhibits MYC transcription at 72 h, and concurrently suppresses the transcription of MYC-associated downstream genes CDC45, ORC2, SRPK1, CAD, and RRM1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MV4-11
-
Concentration:1 nM
-
Incubation Time:0-24 h
-
Result:Produced detectable BRD9 degradation at approximately 4 h.
Produced near-complete BRD9 depletion by 12 h.
Reduced IKZF1 by approximately 50% within 1 h.
Produced near-complete IKZF1 loss by 4 h.
-
Cell Line:MV4-11
-
Concentration:1, 10, 100, 1000 nM
-
Incubation Time:24 h
-
Result:Efficiently degraded BRD9.
Failed to induce appreciable BRD7 degradation.
Failed to induce appreciable BRD4 degradation.
-
Cell Line:MV4-11
-
Concentration:1-1000 nM
-
Incubation Time:24 h
-
Result:Dose-dependently increased apoptosis.
Increased the total apoptotic population to 24.9% at 1 μM.
-
Cell Line:MV4-11
-
Concentration:1-1000 nM
-
Incubation Time:24 h
-
Result:Dose-dependently altered cell-cycle distribution.
Increased S-phase accumulation.
Altered the G1-phase population.
-
Cell Line:OCI-ly10
-
Concentration:1, 10 nM
-
Incubation Time:24, 72 h
-
Result:Mildly reduced MYC mRNA at 10 nM after 24 h.
Suppressed MYC transcription at both 1 and 10 nM after 72 h.
Reduced CDC45, ORC2, SRPK1, CAD, and RRM1 transcription after prolonged exposure.
Parmacokinetics
| Species | Dose | Route | Cmax | Tmax | AUC0-t | T1/2 |
|---|---|---|---|---|---|---|
| Mice[1] | 20 mg/kg | p.o. | 210 ng/mL | 2.3 h | 1140 ng·h/mL | 4.25 h |
In Vivo
PROTAC BRD9 Degrader-12 (30 mg/kg; p.o.; twice daily; 15 days) administered at 30 mg/kg orally twice daily for 15 days achieves >99% tumor growth inhibition and near-complete tumor regression in OCI-ly10 lymphoma xenograft mice without inducing MYC upregulation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/SCID mice (female, 6-8 weeks old, 18-22 g)[1]
-
Dosage:30 mg/kg
-
Administration:p.o.; twice daily; 15 days
-
Result:Exhibits near-complete tumor regression by day 8 of treatment.
Achieves tumor growth inhibition (TGI) exceeding 99% at the end of the 15-day treatment period.
Causes no mortality or significant body weight changes in treated mice.
Induces marked, near-complete degradation of both BRD9 and IKZF1 in excised tumor tissues with no detectable MYC upregulation.
Chemical Information
-
Masse moléculaire 775.89
-
Formule C47H45N5O6
-
SMILES
COC1=CC(C2=CN(C(C3=C2C=CC=C3)=O)C)=CC(OC)=C1CN4CCN(CC4)CC5=CC=C(C=C5)CC6=CC=C7C8=C(C(N7C9CCC(NC9=O)=O)=O)C=CC=C68
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)